FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360999432> ?p ?o ?g. }

• W4360999432 endingPage "104677" @default.
• W4360999432 startingPage "104677" @default.
• W4360999432 abstract "Alemtuzumab is effective in reducing relapse rate and disability, but limited data exist on its effect on cognitive function in relapsing multiple sclerosis (RMS). The present study assessed neurocognitive function and safety associated with alemtuzumab treatment in RMS.This longitudinal, single-arm, prospective study included people with RMS (aged 25-55 years) who were treated with alemtuzumab in clinical practice in the United States of America and Canada. The first participant was enrolled in December 2016. The primary endpoint was the change from baseline to post-baseline (month [M] 12/24) in MS-COGnitive (MS-COG) composite score. Secondary endpoints included Paced Auditory Serial Addition Test (PASAT), Symbol Digit Modalities Test (SDMT), Brief Visuospatial Memory Test-Revised (BVMT-R), Selective Reminding Test (SRT), Controlled Oral Word Association Test (COWAT), and Automated Neuropsychological Assessment Metrics (ANAM) scores. Depression and fatigue were assessed using Hamilton Rating Scale-Depression (HAM-D) and Fatigue Severity Scale (FSS)/Modified Fatigue Impact Scale (MFIS), respectively. Magnetic resonance imaging (MRI) parameters were assessed when available. Safety was assessed throughout the study. Descriptive statistics were used for the pre-specified statistical analyses. Since the study was terminated early (November 2019) because of operational and resource difficulties, post hoc analyses for statistical inference were performed among participants who had a baseline value and at least one complete post-baseline assessment for cognitive parameters, fatigue, or depression.Of the 112 participants enrolled, 39 were considered as the primary analysis population at M12. At M12, a mean change of 0.25 (95% confidence interval [CI]: 0.04, 0.45; p = 0.0049; effect size [ES]: 0.39) was observed in the MS-COG composite score. Improvements were observed in processing speed (based on PASAT and SDMT; p < 0.0001; ES: 0.62), as well as in individual PASAT, SDMT and COWAT scores. An improvement was also noted in HAM-D (p = 0.0054; ES: -0.44), but not in fatigue scores. Among MRI parameters, decreases in burden of disease volume (BDV; ES: -0.12), new gadolinium-enhancing lesions (ES: -0.41) and newly active lesions (ES: -0.07) were observed at M12. About 92% of participants showed stable or improved cognitive status at M12. There were no new safety signals reported in the study. The most common adverse events (≥10% of participants) were headache, fatigue, nausea, insomnia, urinary tract infection, pain in extremity, chest discomfort, anxiety, dizziness, arthralgia, flushing, and rash. Hypothyroidism (3.7%) was the most frequent adverse event of special interest.The findings from this study suggest that alemtuzumab has a positive impact on cognitive function with significant improvements in processing speed and depression in people with RMS over a period of 12 months. The safety profile of alemtuzumab was consistent with previous studies." @default.
• W4360999432 created "2023-03-30" @default.
• W4360999432 creator A5012087557 @default.
• W4360999432 creator A5014372247 @default.
• W4360999432 creator A5016633166 @default.
• W4360999432 creator A5030980805 @default.
• W4360999432 creator A5035458785 @default.
• W4360999432 creator A5041624640 @default.
• W4360999432 creator A5047915478 @default.
• W4360999432 creator A5052099043 @default.
• W4360999432 creator A5053253768 @default.
• W4360999432 creator A5061524175 @default.
• W4360999432 creator A5067117782 @default.
• W4360999432 creator A5090557874 @default.
• W4360999432 date "2023-05-01" @default.
• W4360999432 modified "2023-09-30" @default.
• W4360999432 title "Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results" @default.
• W4360999432 cites W139758990 @default.
• W4360999432 cites W155259919 @default.
• W4360999432 cites W1554919938 @default.
• W4360999432 cites W1580539462 @default.
• W4360999432 cites W1666336517 @default.
• W4360999432 cites W1976470756 @default.
• W4360999432 cites W2013999515 @default.
• W4360999432 cites W2025070618 @default.
• W4360999432 cites W2025635957 @default.
• W4360999432 cites W2032557244 @default.
• W4360999432 cites W2036284753 @default.
• W4360999432 cites W2042906937 @default.
• W4360999432 cites W2046748764 @default.
• W4360999432 cites W2049904609 @default.
• W4360999432 cites W2051984800 @default.
• W4360999432 cites W2057115987 @default.
• W4360999432 cites W2062453566 @default.
• W4360999432 cites W2080138496 @default.
• W4360999432 cites W2084315798 @default.
• W4360999432 cites W2087764276 @default.
• W4360999432 cites W2090129031 @default.
• W4360999432 cites W2090372204 @default.
• W4360999432 cites W2101483035 @default.
• W4360999432 cites W2105372935 @default.
• W4360999432 cites W2106948231 @default.
• W4360999432 cites W2107026277 @default.
• W4360999432 cites W2107422246 @default.
• W4360999432 cites W2114613490 @default.
• W4360999432 cites W2114753322 @default.
• W4360999432 cites W2121127042 @default.
• W4360999432 cites W2130632081 @default.
• W4360999432 cites W2138736986 @default.
• W4360999432 cites W2144328025 @default.
• W4360999432 cites W2148766438 @default.
• W4360999432 cites W2152906203 @default.
• W4360999432 cites W2154299978 @default.
• W4360999432 cites W2158202057 @default.
• W4360999432 cites W2191972178 @default.
• W4360999432 cites W2265012467 @default.
• W4360999432 cites W2282142519 @default.
• W4360999432 cites W2515660815 @default.
• W4360999432 cites W2529921999 @default.
• W4360999432 cites W2530962812 @default.
• W4360999432 cites W2574090906 @default.
• W4360999432 cites W2580622791 @default.
• W4360999432 cites W2588292672 @default.
• W4360999432 cites W2595073340 @default.
• W4360999432 cites W2626225244 @default.
• W4360999432 cites W2744884072 @default.
• W4360999432 cites W2746924405 @default.
• W4360999432 cites W2753105249 @default.
• W4360999432 cites W2755388157 @default.
• W4360999432 cites W2784062509 @default.
• W4360999432 cites W2800924304 @default.
• W4360999432 cites W2892524347 @default.
• W4360999432 cites W2920934533 @default.
• W4360999432 cites W2922071298 @default.
• W4360999432 cites W2947647736 @default.
• W4360999432 cites W2970521249 @default.
• W4360999432 cites W2983891338 @default.
• W4360999432 cites W3010420803 @default.
• W4360999432 cites W3020894047 @default.
• W4360999432 cites W3020969316 @default.
• W4360999432 cites W3022880097 @default.
• W4360999432 cites W3023383251 @default.
• W4360999432 cites W3023568901 @default.
• W4360999432 cites W3026037032 @default.
• W4360999432 cites W3026066403 @default.
• W4360999432 cites W3045363217 @default.
• W4360999432 cites W3084818633 @default.
• W4360999432 cites W3104226692 @default.
• W4360999432 cites W3134185790 @default.
• W4360999432 cites W3156339338 @default.
• W4360999432 cites W3157786956 @default.
• W4360999432 cites W3196920070 @default.
• W4360999432 cites W3198197412 @default.
• W4360999432 cites W4211048507 @default.
• W4360999432 cites W4220696425 @default.
• W4360999432 cites W4225012132 @default.
• W4360999432 cites W4253381763 @default.
• W4360999432 doi "https://doi.org/10.1016/j.msard.2023.104677" @default.

• next